Clinical Trial: Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187856) titled 'Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus' on Aug. 28.

Brief Summary: Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes Mellitus (T2DM)

Intervention: DRUG: PG-102

PG-102 is administered subcutaneously once weekly with a titration regimen.

DRUG: Placebo

Placebo is administered subcutaneously once weekly.

DRUG: Semaglutide

Open-label semaglutide is administered subcutaneously once weekly with titration regimen.

Recruitment Status: NOT_YET_RECRUITING

Spo...